- Preamble [SYSTEM]
- Fund & Investor Interest
- Street Moves
- Solebury Trout Updates
- Market Commentary
- IPO News
- Expert Interactions
- Banker Comments & Notes
- Conference Snippet
- Industry Snippets
- Social Media
- Solebury Trout Talks
IPO News: IPO Filings - 4 Offerings
Agora
NASDAQ: API
Size: $100mm
Underwriters: Morgan Stanley | Bank of America
Major Holders: Soundscape Limited | Morningside | SIG | Shunwei Capital Partners | Coatue (Asia) | Easy Dynamic International
Description: Agora’s platform provides developers simple-to-use, highly customizable and widely compatible application programming interfaces, or APIs, to embed real-time video and voice functionalities into their applications without the need to develop the technology or build the underlying infrastructure themselves.
Reference Link: F-1
Fusion Pharmaceuticals
NASDAQ: FUSN
Size: $100mm
Underwriters: Morgan Stanley | Jefferies | Cowen | Wedbush
Major Holders: HealthCap | Adams Street Partners | Varian Medical Systems | Johnson & Johnson | CPPIB | TPG | OrbiMed | Seroba Life Sciences
Description: Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
Reference Link: S-1
PolyPid Ltd.
NASDAQ: PYPD
Size: $57.5mm
Underwriters: Barclays | BMO | Raymond James | National Securities | AGP
Major Holders: Aurum Ventures | Shavit Capital Management | Shirat Hachaim
Description: PolyPid is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using their proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology.
Reference Link: F-1
Akouos
NASDAQ: AKUS
Size: $100mm
Underwriters: Bank of America | Cowen | Piper Sandler | BTIG
Major Holders: 5AM Ventures | NEA | Pivotal bioVenture Partners Fund | Sofinnova | RA Capital Management | Novartis | Fidelity
Description: Akouos is a precision genetic medicine company dedicated to their mission of developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
Reference Link: S-1